Remove Diagnose Remove Diagnosis Remove Patients Remove Screening
article thumbnail

Decisional Regret Two-Year after Diagnosis with Low-risk Prostate Cancer in a Population-based Sample [Cancer research (not screening)]

Annals of Family Medicine

Context: Men newly diagnosed with low-risk prostate cancer (LPC) have multiple treatment options available, each with potential effects on quality of life (QOL). Objective: To assess decisional regret (DR) and QOL changes by treatment choice (surgery, radiation or active surveillance) two years after diagnosis in a cohort of men with LPC.

Diagnosis 130
article thumbnail

Assessment of Project ECHO(R) Opioid Use Disorder Sessions for Primary Care Teams [Education and training]

Annals of Family Medicine

A critical shortage of clinicians who specialize in treating patients with OUD exacerbates this issue. While primary care (PC) settings have the potential to bridge this gap in care, many care teams lack the education and training required to effectively manage patients with OUD.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Screen Time

Adventures of a Sick Doctor

I have been working in cancer screening for seven months now, and I have had the opportunity to reflect on what that means for me, as a cancer patient myself. For a start, my cancer is colorectal not cervical, and besides it is unrelated to screening as I was diagnosed at an age that is outside of the screening parameters.

Screening 100
article thumbnail

Portable Assay Offers Rapid, Low-Cost TB Diagnoses

Physician's Weekly

A novel, portable assay can deliver TB diagnoses in under an hour at low cost using samples of blood, saliva, or sputum, according to a recent study. The post Portable Assay Offers Rapid, Low-Cost TB Diagnoses first appeared on Physician's Weekly. An estimated 4.2

article thumbnail

Rare Diseases: Pathways to accelerating diagnoses 

Myriad Genetics

Recently, the Today Show highlighted Courtney (she asked that only first names be used), who visited 17 different doctors over three years to help diagnose her young son Alex, who she was watching suffer and decline before her eyes. None of them. It was the AI program ChatGPT.

article thumbnail

A New Outlook: How Carrier Screening Shaped One Family’s Future

Myriad Genetics

We went through the pediatrician, the physical therapist, and none of those people brought up carrier screening. A carrier screen is a genetic test that looks at a couple’s DNA to see if they are carrying any genetic mutations that could be inherited by their baby. “We started asking questions because he still wasn’t walking.

article thumbnail

AMPLIFY™ Technology Enhances Prenatal Screening for 22q11.2 Microdeletion

Myriad Genetics

Typically, the way to diagnose 22q prenatally is through chorionic villus sampling or an amniocentesis. Less invasive options like prenatal cell-free DNA (cfDNA) screens can also be used to help identify the microdeletion. Thus, the value of using cfDNA screens for 22q has been marginal. Such is the case with the 22q11.2